Is Ascletis Pharma Inc. (ASCLF) a Buy, Sell, or Hold?
OTC : ASCLF
Ascletis Pharma Inc.
$1.205 USD
$0 (0.0%)
- Volume
- 225
- Average Volume
- 271
- Market Capitalization
- $1.26B
- P/E Ratio
- -24.76
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $2.50
- Year Low
- $1.07
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $15.05
Company Overview
OTC
Jinzi J. Wu
Biotechnology
Healthcare
ASCLF
202
CN
USD
Liquidity Metrics
0.00
15.05
15.04
11.31
0.00
Sales & Valuation
$1.98M
4752.16
4.67
-25.38
-0.39
Profitability
-$0.36
-$350.59M
-17745.56%
-17720.61%
-18.93%
-17.41%
P/E Metrics
-24.76
0.72
0.72
Analyst Price Target & Rating
0/5
0 Analysts
%
Financial Health Scores
37.74
1/9
$1.79B
$2.07B
$129.94M
-$883.88M
Key Metrics (TTM)
$8.11B
3996.55
-17.18
15.05
-18.93%
-24.90%
-4.02%
-3.98%
2509 days
Company Executives
| Name | Title |
|---|---|
| George Zhengzhi Hill | Senior Consultant & Chief Medical Advisor |
| Jinzi Wu | Founder, Chairman & Chief Executive Officer |
| Hejingdao Wu | Senior Vice President of Operations & Executive Director |
| Ming Fai Chung | Company Secretary |
| John Gargiulo | Chief Business Officer |
| Kristjan Sigurdur Gudmundsson | Senior Consultant & Head of Discovery |
Poll Results
No votes yet today — be the first to share your view!
About Ascletis Pharma Inc. (OTC:ASCLF) Stock
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company's commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, and ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma; ASC61 for advanced solid tumors; and ASC40, an oral small molecule for the treatment of acne. Ascletis Pharma Inc. was founded in 2013 and is based ... in Hangzhou, the People's Republic of China.
2026-06-23 06:10:00
Phase I trial consists of two parts. Part A is a single ascending dose (SAD) study of ASC35 once-monthly Self-Assembling Lipid Depot (SALD) formulation; Part B is a head-to-head study of multiple ascending doses (MAD) of ASC35 once-monthly SALD formulation compared to the U.S. Food and Drug Administration (FDA)-authorized tirzepatide once-weekly formulation.
2026-06-07 20:10:00
HONG KONG, June 7, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces the presentation of three key studies at the American Diabetes Association (ADA) 2026 Scientific Sessions (taking place June 5-8, 2026, in New Orleans, Louisiana), highlighting its differentiated portfolio in obesity treatment, including small-molecule candidates, a peptide therapeutic, and an oral peptide delivery-enhancing technology. The data attracted considerable interest from leading experts at the meeting and further underscored Ascletis' innovation capabilities in metabolic disease therapeutics.
Frequently Asked Questions
-
What is the current Ascletis Pharma Inc. (ASCLF) stock price?
-
Ascletis Pharma Inc.(OTC:ASCLF) stock price is $1.205 in the last trading session. During the trading session, ASCLF stock reached the peak price of $2.5 while $1.07 was the lowest point it dropped to. The percentage change in ASCLF stock occurred in the recent session was 0.0% while the dollar amount for the price change in ASCLF stock was $0.
-
ASCLF's industry and sector of operation?
-
The OTC listed ASCLF is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ASCLF?
-
George Zhengzhi Hill | Senior Consultant & Chief Medical Advisor
Jinzi Wu | Founder, Chairman & Chief Executive Officer
Hejingdao Wu | Senior Vice President of Operations & Executive Director
Ming Fai Chung | Company Secretary
John Gargiulo | Chief Business Officer -
How many employees does ASCLF have?
-
Number of ASCLF employees currently stands at 202. ASCLF operates from 12/F, Building D, Hangzhou, ENG 311200, CN.
-
Link for ASCLF official website?
-
Official Website of ASCLF is: https://www.ascletis.com
-
How do I contact ASCLF?
-
ASCLF could be contacted at phone #86 571 8538 9730 and can also be accessed through its website. ASCLF operates from 12/F, Building D, Hangzhou, ENG 311200, CN.
-
How many shares of ASCLF are traded daily?
-
The average number of ASCLF shares traded daily for last 3 months was 271.
-
What is the market cap of ASCLF currently?
-
The market value of ASCLF currently stands at $1.26B with its latest stock price at $1.205